肝硬化1级腹水与复发性腹水的结局与死亡率
该研究对547例肝硬化门诊患者进行事后分析,中位随访29个月。1级腹水患者60个月无移植生存率与2/3级腹水无显著差异(36% vs 43%),但均显著低于无腹水者(68%,P<.001)。复发性腹水与药物应答性腹水36个月无移植生存率无显著差异(78% vs 62%),难治性腹水生存率显著更低(23%)。
要点
- 1级腹水患者60个月无移植生存率36%,与2/3级腹水43%无显著差异,但显著低于无腹水者68%。
- 1级腹水患者系统炎症程度和并发症发生率高于无腹水者,但低于2/3级腹水者。
- 复发性腹水与药物应答性腹水36个月无移植生存率无显著差异(78% vs 62%);难治性腹水生存率显著更低(23%)。
核心结论
- 肝硬化1级腹水与系统炎症、更多并发症和死亡率增加相关,死亡率与2/3级腹水无显著差异。
- 复发性腹水与药物应答性腹水死亡率无显著差异,难治性腹水死亡率显著更高。
研究设计与样本
- 事后分析,纳入547例肝硬化门诊患者(无腹水259例,1级腹水54例,2/3级腹水234例),来自意大利2003年3月至2017年9月的管理项目研究。
- 中位随访29个月,每至少6个月评估一次,每年至少两次腹部超声,随访至死亡、肝移植或2018年3月。
主要发现
- 60个月无移植生存率:1级腹水36%,2/3级腹水43%,无腹水68%;1级与2/3级比较无显著差异,两者与无腹水比较均P<.001。
- 1级腹水患者系统炎症程度和并发症发生率显著高于无腹水者,但显著低于2/3级腹水者。
- 无腹水者与1级腹水者进展为2/3级腹水的比例分别为10%和14%,无显著差异。
- 36个月无移植生存率:药物应答性腹水78%,复发性腹水62%,两者无显著差异;难治性腹水23%,显著低于药物应答性(P<.001)和复发性(P=.022)。
关键数值与推荐
- 复发性腹水定义:12个月内 despite 限钠饮食和充足利尿剂剂量仍至少3次复发腹水。
临床怎么用
- 1级腹水应视为预后不良标志,需监测系统炎症和并发症,不应仅因腹水量少而忽视。
- 复发性腹水与药物应答性腹水死亡率相近,但难治性腹水预后显著更差,需积极评估移植等治疗。
局限性
- 为事后分析,非预设研究。
- 样本来自单国管理项目,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ascites has been classified according to quantity and response to medical therapy. Despite its precise definitions, little is known about the effects of grade 1 ascites or recurrent ascites (i.e. ascites that recurs at least on 3 occasions within a 12-month period despite dietary sodium restriction and adequate diuretic dosage) on patient outcome. We studied progression of grade 1 ascites and recurrent ascites in a large cohort of outpatients with cirrhosis. METHODS: We performed a post-hoc analysis of data from 547 outpatients with cirrhosis (259 without ascites, 54 patients with grade 1 ascites, 234 with grade 2 or 3 ascites) who participated a care management program study in Italy from March 2003 through September 2017. We collected demographic, clinical, and laboratory data and patients were evaluated at least every 6 months. Patients received abdominal ultrasound analysis at study inclusion and at least twice a year. Number and volume of paracentesis were collected, when available. Patients were followed until death, liver transplantation, or March 2018. The median follow-up time was 29 months. Primary outcomes were mortality and development of complications of cirrhosis. RESULTS: There was no significant difference in 60-month transplant-free survival between patients with grade 1 vs grade 2 or 3 ascites (36% vs 43%) but survival was significantly lower when both groups were compared with patients without ascites (68%; P < .001 for both comparisons). However, the grade of systemic inflammation and the rate of complications were significantly greater in patients with grade 1 ascites than in patients without ascites, but significantly lower than in patients with grade 2 or 3 ascites. Development of grade 2 or 3 ascites did not differ significantly between patients with no ascites vs grade 1 ascites (10% vs 14%). There was no significant difference in 36-month transplant-free survival between patients with ascites responsive to medical treatment vs recurrent ascites (78% vs 62%), whereas patients with refractory ascites had significantly lower survival than patients with responsive or recurrent ascites (23%; responsive vs refractory ascites P<.001; recurrent vs refractory ascites P = .022). CONCLUSIONS: In an analysis of data from a large cohort of outpatients with cirrhosis, we found that grade 1 ascites is associated with systemic inflammation, more complications, and increased mortality compared with no ascites. Mortality does not differ significantly between patients with recurrent ascites vs ascites responsive to medical treatment.
引用
- Tonon M, Piano S, Gambino CG, et al. Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020. PMID: 32272250. doi:10.1016/j.cgh.2020.03.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。